← Back to Screener
SANUWAVE Health, Inc. Common Stock (SNWV)
Price$18.02
Favorite Metrics
Price vs S&P 500 (26W)-45.66%
Price vs S&P 500 (4W)-19.11%
Market Capitalization$157.02M
P/E Ratio (Annual)13.29x
All Metrics
P/CF (Annual)40.51x
Book Value / Share (Quarterly)$0.19
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)38.05%
Cash Flow / Share (Quarterly)$0.23
Price vs S&P 500 (YTD)-41.42%
Gross Margin (TTM)77.11%
Net Profit Margin (TTM)26.82%
EPS (TTM)$1.27
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$1.27
Revenue Growth (5Y)61.12%
EPS (Annual)$1.30
ROI (Annual)50.10%
Gross Margin (Annual)77.11%
Net Profit Margin (5Y Avg)-93.37%
Cash / Share (Quarterly)$1.39
P/E Basic Excl Extra (TTM)13.29x
Revenue Growth QoQ (YoY)26.81%
P/E Normalized (Annual)13.29x
ROA (Last FY)31.63%
Revenue Growth TTM (YoY)34.98%
EBITD / Share (TTM)$1.22
Operating Margin (TTM)9.70%
Cash Flow / Share (Annual)$0.23
P/B Ratio96.98x
P/B Ratio (Quarterly)158.07x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.79x
Net Interest Coverage (TTM)0.30x
ROA (TTM)34.53%
EV / EBITDA (TTM)15.30x
EPS Incl Extra (Annual)$1.30
Current Ratio (Annual)1.38x
Quick Ratio (Quarterly)0.97x
3-Month Avg Trading Volume0.07M
52-Week Price Return-40.02%
EV / Free Cash Flow (Annual)86.36x
P/E Incl Extra (TTM)13.29x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$2.07
P/S Ratio (Annual)3.56x
Asset Turnover (Annual)1.18x
52-Week High$46.59
Operating Margin (5Y Avg)-33.61%
EPS Excl Extra (Annual)$1.30
CapEx CAGR (5Y)105.57%
26-Week Price Return-41.68%
Quick Ratio (Annual)0.97x
13-Week Price Return-37.77%
Total Debt / Equity (Annual)13.56x
Current Ratio (Quarterly)1.38x
Enterprise Value$167.017
Revenue / Share Growth (5Y)3.84%
Asset Turnover (TTM)1.29x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.00x
Pretax Margin (Annual)27.01%
Cash / Share (Annual)$1.39
3-Month Return Std Dev43.11%
Gross Margin (5Y Avg)71.71%
Net Income / Employee (TTM)$0
ROE (Last FY)729.65%
Net Interest Coverage (Annual)0.18x
EPS Basic Excl Extra (Annual)$1.30
P/FCF (TTM)41.55x
Receivables Turnover (TTM)10.07x
EV / Free Cash Flow (TTM)86.36x
Total Debt / Equity (Quarterly)13.56x
EPS Incl Extra (TTM)$1.27
Receivables Turnover (Annual)10.07x
ROI (TTM)25.91%
P/S Ratio (TTM)3.56x
Pretax Margin (5Y Avg)-93.26%
Revenue / Share (Annual)$4.85
Tangible BV / Share (Annual)$-0.10
Forward P/E45.77x
Price vs S&P 500 (52W)-69.85%
P/E Ratio (TTM)13.29x
Year-to-Date Return-38.77%
5-Day Price Return0.61%
EPS Normalized (Annual)$1.30
ROA (5Y Avg)-77.17%
Net Profit Margin (Annual)26.82%
Month-to-Date Return5.67%
Cash Flow / Share (TTM)$-0.08
EBITD / Share (Annual)$1.20
Operating Margin (Annual)9.70%
LT Debt / Equity (Annual)10.08x
P/CF (TTM)40.51x
P/E Excl Extra (TTM)13.29x
LT Debt / Equity (Quarterly)10.08x
EPS Basic Excl Extra (TTM)$1.27
P/TBV (Quarterly)88.90x
P/B Ratio (Annual)158.07x
Inventory Turnover (TTM)2.00x
Pretax Margin (TTM)27.01%
Book Value / Share (Annual)$0.19
Price vs S&P 500 (13W)-38.46%
Beta1.54x
P/FCF (Annual)81.19x
Revenue / Share (TTM)$5.01
ROE (TTM)377.33%
52-Week Low$16.27
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
SNWVSANUWAVE Health, Inc. Common Stock | 3.56x | 61.12% | 77.11% | 9.70% | $18.02 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
SANUWAVE Health develops noninvasive ultrasound and shock wave technology for regenerative medicine, with a focus on wound healing. The company's two primary products, UltraMIST and PACE, are the only FDA-approved directed energy systems for this indication. This regulatory exclusivity provides a differentiated market position in the specialized wound care sector.